TABLE 3.
Prophylactic dosing during ASPIRE by parent study and treatment regimen
| Parent study | A‐LONG a | Kids A‐LONG | |||
|---|---|---|---|---|---|
| Treatment regimen | IP | WP | MP b | Aged <6 y | Aged 6 to <12 y |
| IP | IP | ||||
| Number of subjects, n | 110 | 27 | 21 | 29 c , d | 30 e |
| Median (IQR) dosing interval, d | 3.5 (3.5‐5.0) | 7.0 (7.0‐7.1) | 5.0 (4.0‐6.9) | 3.5 (3.5‐3.5) | 3.5 (3.5‐3.5) |
| Median (IQR) weekly dose, IU/kg | 79.5 (73.7‐100.9) | 65.7 (61.9‐67.2) | 70.6 (62.3‐90.4) | 101.9 (88.7‐118.7) | 94.9 (81.7‐109.1) |
Abbreviations: IP, individualized prophylaxis; IQR, interquartile range; MP, modified prophylaxis; WP, weekly prophylaxis.
a
Twenty‐one subjects switched treatment regimens once during ASPIRE.
b
MP was not available in A‐LONG.
c
One subject switched from IP to MP.
d
The two subjects <6 y of age receiving MP had dosing intervals of 2.3‐5.5 d and weekly doses of 81.5‐118.7 IU/kg.
e
The single subject 6 to <12 y of age receiving MP had a dosing interval of 3.5 d and a weekly dose of 84.5 IU/kg.